The global spread of drug-resistant influenza
暂无分享,去创建一个
Rustom Antia | Ira M Longini | Jesse D Bloom | J. Bloom | I. Longini | D. Chao | R. Antia | Dennis L Chao | Beth F Kochin | Beth F. Kochin
[1] Cecile Viboud,et al. Phylogenetic Analysis Reveals the Global Migration of Seasonal Influenza A Viruses , 2007, PLoS pathogens.
[2] F. Hayden,et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.
[3] R. Saito,et al. Genetic Makeup of Amantadine-Resistant and Oseltamivir-Resistant Human Influenza A/H1N1 Viruses , 2010, Journal of Clinical Microbiology.
[4] V. Caron,et al. United states. , 2018, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[5] Jessica B. Graham. The Global Spread of Drug-Resistant Influenza , 2011 .
[6] A. Monto,et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. , 2002, Antiviral research.
[7] C. Viboud,et al. Explorer The genomic and epidemiological dynamics of human influenza A virus , 2016 .
[8] Mark A. Miller,et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. , 2007, Molecular biology and evolution.
[9] G. Kobinger,et al. Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets , 2010, PLoS pathogens.
[10] A. Nizam,et al. Containing Pandemic Influenza at the Source , 2005, Science.
[11] W. Barclay,et al. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness , 2010, The Journal of antimicrobial chemotherapy.
[12] Guy Boivin,et al. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. , 2011, The Journal of infectious diseases.
[13] Pia Abel zur Wiesch,et al. Population biological principles of drug-resistance evolution in infectious diseases. , 2011, The Lancet. Infectious diseases.
[14] H. Klenk,et al. Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.
[15] M. Elizabeth Halloran,et al. Containing Pandemic Influenza at the Source , 2005, Science.
[16] S. van der Werf,et al. Enzymatic Properties of the Neuraminidase of Seasonal H1N1 Influenza Viruses Provide Insights for the Emergence of Natural Resistance to Oseltamivir , 2008, PLoS pathogens.
[17] Makoto Ujike,et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir , 2010, Virology Journal.
[18] A. Nicoll,et al. Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[19] E. Holmes,et al. Homologous Recombination Is Very Rare or Absent in Human Influenza A Virus , 2008, Journal of Virology.
[20] Nicole M. Bouvier,et al. Oseltamivir-Resistant Influenza A Viruses Are Transmitted Efficiently among Guinea Pigs by Direct Contact but Not by Aerosol , 2008, Journal of Virology.
[21] G. Boivin,et al. A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus , 2003, Antiviral therapy.
[22] A. Monto,et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.
[23] J. van de Kassteele,et al. Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.
[24] M. Halloran,et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. , 2006, American journal of epidemiology.
[25] J. Oxford,et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. , 2002, Antiviral research.
[26] G. Boivin,et al. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. , 2010, The Journal of infectious diseases.
[27] A. Lapedes,et al. Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.
[28] A. Moscona,et al. Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.
[29] Jonathan Dushoff,et al. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] G. Kochs,et al. Oseltamivir-Resistant Variants of the 2009 Pandemic H1N1 Influenza A Virus Are Not Attenuated in the Guinea Pig and Ferret Transmission Models , 2010, Journal of Virology.
[31] Ryo Takano,et al. Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses , 2010, PLoS pathogens.
[32] M. Pascual,et al. Global Migration Dynamics Underlie Evolution and Persistence of Human Influenza A (H3N2) , 2010, PLoS pathogens.
[33] H. Niman. Emergence and Fixing of Antiviral Resistance in Influenza A Via Recombination and Hitch Hiking , 2009 .
[34] P. Ward,et al. Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.
[35] D. Cummings,et al. Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.
[36] M. Halloran,et al. The Global Transmission and Control of Influenza , 2011, PloS one.
[37] R. Webster,et al. Oseltamivir–Resistant Pandemic H1N1/2009 Influenza Virus Possesses Lower Transmissibility and Fitness in Ferrets , 2010, PLoS pathogens.
[38] R. Saito,et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[39] David Baltimore,et al. Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.
[40] J. Oxford,et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.
[41] P. Collins,et al. Structural basis for oseltamivir resistance of influenza viruses. , 2009, Vaccine.
[42] R. Epstein,et al. Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–2005 , 2008, Emerging infectious diseases.